Immunovant
Tracked across 2 events · 23 articles · First seen Apr 02, 2026 · Last active Sep 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Immunovant announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE). The randomized, double-blind, placebo-controlled global study enrolled 57 adult patients who were randomized to IMVT-1402 or…
Impact: Immunovant is the central actor, reporting failed primary endpoint results for IMVT-1402 in CLE and deciding to stop development in that indication. The setback removes a pipeline opportunity but leaves other autoimmune programs on track.
Sep 23, 2026 · 7 articles
Business
Impact: Immunovant's batoclimab Phase 3 studies failed to meet their primary endpoint for thyroid eye disease, which is a significant setback for the company.
Apr 02, 2026 · 16 articles
85
Immunovant reported topline resultsImmunovant IMVT-1402 CLE Trial Miss
ERGEN INTELLIGENCE
Track Immunovant live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard